.png){kind=icon}
Return
Therapy for CPPD: Options and Evidence
.png){kind=icon}
PRE
AI
DOI：10.1007/s11926-018-0739-z.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Purpose of Review Current evidence and accumulated experience for the management of calcium pyrophosphate deposition disease (CPPD) are presented. Recent Findings Contrary to other rheumatic inflammatory conditions that account for high interest and growing research, advances in treating CPPD are still very limited and mostly derive from those achieved in gout. Summary Once formed, calcium pyrophosphate crystals cannot be dissolved; therefore, management relies on the control of crystal-derived inflammation. Besides classical agents-such as colchicine, glucocorticoids, or NSAIDs-the use of targeted therapies, mostly against interleukin-1, has provided a relevant relief for refractory CPPD patients in recent years. Meanwhile. former enthusiasm about conventional disease-modifying agents such as methotrexate is currently controversial.
Keywords:
Calcium pyrophosphate
Chondrocalcinosis
Therapy
Colchicine
Methotrexate
Anakinra
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.9
Papers:
1.1K
Citations:
4.3K
Organization
Cited Papers
A facile one-step way to anchor noble metal (Au, Ag, Pd) nanoparticles on a reduced graphene oxide mat with catalytic activity for selective reduction of nitroaromatic compounds.png)
CrystEngComm
CrystEngCommIF0
PREAI
ShareSaveShareSaveShareSaveShareSaveAnakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failureJOINT BONE SPINE
JOINT BONE SPINEIF4.3
PREAI
ShareSave
View more